awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45
Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
P2860
Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
950840a0d9393e15a79c7965c7dabcfc6a129aff
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.